Global Community

Risks -27% stock price drop over past year – industry-wide pressure Cyclicality – tied to industrial demand cycles Moderate growth – not a high-growth tech stock Assumptions Revenue by 2029: Estimate: ~SEK 26–28 billion Current Revenue: SEK 20.44 billion Expected Growth: ~4.3–7.2% annually Growth Drivers: Strong demand for polymer solutions in automotive, construction, and energy Growth in engineered products and thermoplastic elastomers Sustainability and recycling focus aligned with EU regulations (ESG boost) Earnings by 2029: Estimate: ~SEK 3–3.5 billion Current Earnings: SEK 2.22 billion Expected Growth: ~7.2% annually Key Factors: Stable gross margins (21–23%) Facility consolidation and improved operational efficiency Acquisitions (M&A) and shift toward high-margin products Catalysts Reliable dividend yield – 4.3% Low debt (Debt/Equity = 18.7%) Consistent growth through green innovation and acquisitions

It was an innovator, but not is is mostly hype, with stagnating car sales.

Catalysts Are there any products or services that could move sales or earnings meaningfully? Are there any industry tailwinds this stock is benefitting or hindered from?

Gewinnwarnung 2024: Gestiegende Transportkosten Preissensititivät d. Kunden Geringes Wirtschaftswachstum 2-4 % CAGR "Low End of Guidance hard to achive" Gewinnwarnungen auch von Produzenten BASF, Lanxess, Evonik Umsatzwachstum "nur" 5,1 % (< erwartete 9...10%) stagnierender Marktausblick Chemieindustrie (gestiegende Energiekosten), ggf.

In 5 years, the company should significantly expand its portfolio of stores in countries other than Poland, open up to new markets, and introduce e-commerce and applications of its brands to new countries. Due to the fact that it has five brands, each targeting a different audience, the company has a wide scope for action and further development, as the brands it has are not in competition with each other, but complement each other perfectly.

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.

DCF based on slighlty more optimistic outlook than analysts Using my standard discount rate of 15% Terminal PE of 20

Everything that could have gone wrong, went wrong. The assets are now owned by the bank and creditors Poorly managed company with very slow decission making , unable to react that have wasted a Great future.

Assumptions Prognos och värdering Tillväxt: För innevarande år bör tillväxten landa på drygt 30%. Efter det räknar vi på 25% och sedan 20%, totalt något under bolagets mål om 25% tillväxt.